Published in Breast Cancer Res on July 09, 2012
Molecular drivers of lobular carcinoma in situ. Breast Cancer Res (2015) 0.86
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol (2015) 0.81
Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol (2015) 0.80
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol (2014) 0.79
Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors. PLoS One (2015) 0.76
Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Res (2016) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Lobular carcinoma in situ: A rare form of mammary cancer. Am J Pathol (1941) 3.35
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
Prognostic classification of breast ductal carcinoma-in-situ. Lancet (1995) 2.70
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer (1978) 2.23
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol (1978) 1.78
Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol (1999) 1.76
Breast cancer precursors revisited: molecular features and progression pathways. Histopathology (2010) 1.72
Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol (1991) 1.65
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer (2001) 1.64
Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol (2001) 1.51
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer (2004) 1.40
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res (1998) 1.33
Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol (2002) 1.24
Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg (1979) 1.23
A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med (2010) 1.18
Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch (2002) 1.11
Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes Chromosomes Cancer (2006) 1.07
Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol (2008) 1.05
Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch (2006) 1.04
The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract (2005) 1.01
Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat (2007) 1.01
Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Hum Mutat (2007) 0.98
Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics (2011) 0.98
Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. Biotechniques (2007) 0.97
Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol (2001) 0.95
Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol (2001) 0.92
Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases. Am J Clin Pathol (2009) 0.89
Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. Mod Pathol (2008) 0.89
The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology (2009) 0.83
Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol (2005) 0.81
Is there a low-grade precursor pathway in breast cancer? Ann Surg Oncol (2011) 0.81
Expert review of histologic slides and Papanicolaou tests in the context of litigation or potential litigation. Surgical Pathology Committee and Cytopathology Committee of the College of American Pathologists. Arch Pathol Lab Med (2000) 0.77
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Two-stage designs for gene-disease association studies. Biometrics (2002) 3.67
Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol (2005) 3.65
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol (2011) 3.22
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 2.70
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst (2004) 2.37
Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg (2008) 2.33
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol (2011) 2.24
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol (2002) 2.20
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst (2009) 2.18
Management of the clinically node-negative axilla: what have we learned from the clinical trials? Oncology (Williston Park) (2014) 2.17
Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park) (2011) 2.16
Does aggressive local therapy improve survival in metastatic breast cancer? Surgery (2002) 2.13
Ductal lavage findings in women with mammographic microcalcifications undergoing biopsy. Ann Surg Oncol (2005) 2.13
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Correlates of between-surgeon variation in breast cancer treatments. Med Care (2006) 2.08
Two-stage designs for gene-disease association studies with sample size constraints. Biometrics (2004) 2.08
Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res (2006) 2.07
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008) 2.06
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Should intraoperative frozen section evaluation of breast lumpectomy margins become routine practice? Am J Clin Pathol (2012) 1.99
Reporting participation in case-control studies. Epidemiology (2002) 1.99
Beauty and the beast: management of breast cancer after plastic surgery. Ann Surg (2008) 1.98
The Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer: Perspectives for Pathologists. Arch Pathol Lab Med (2014) 1.98
Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol (2009) 1.96
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol (2002) 1.93
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J (2010) 1.90
An informed decision? Breast cancer patients and their knowledge about treatment. Patient Educ Couns (2006) 1.87
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer (2005) 1.86
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 1.85
Patterns and correlates of patient referral to surgeons for treatment of breast cancer. J Clin Oncol (2007) 1.84
Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol (2013) 1.84
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2004) 1.82
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
Regulation of adipogenesis by lymphatic fluid stasis: part I. Adipogenesis, fibrosis, and inflammation. Plast Reconstr Surg (2012) 1.78
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev (2007) 1.76
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys (2007) 1.71
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology (2005) 1.69
Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer. Qual Life Res (2005) 1.67
Attribution of deaths following cancer treatment. J Natl Cancer Inst (2002) 1.63
Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol (2010) 1.61
Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci U S A (2013) 1.60
Symptom experience and quality of life of women following breast cancer treatment. J Womens Health (Larchmt) (2007) 1.58
Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology (2010) 1.58
Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population- based study. J Clin Oncol (2009) 1.56
Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction. Cancer (2007) 1.54
Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer. Cancer (2008) 1.54
The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A (2008) 1.53
Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg (2011) 1.53
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol (2005) 1.53
What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol (2009) 1.52
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50